Access Industries and Len Blavatnik Disclose 10.4% Stake in Hemab Therapeutics Post-IPO

summarizeSummary

Access Industries and Len Blavatnik have become a major shareholder in Hemab Therapeutics, acquiring a 10.4% stake, including a $19.8 million direct investment in the company's recent IPO at $18.00 per share.

check_boxKey Events

• New 10.4% Beneficial Ownership

  AI DEN-MAB LLC and affiliated entities, including Len Blavatnik, reported beneficial ownership of 4,876,344 shares, representing 10.4% of Hemab Therapeutics Holdings, Inc. common stock following the company's IPO on May 4, 2026.

• Significant IPO Investment

  The reporting group purchased 1,100,000 shares directly in the company's initial public offering at the public offering price of $18.00 per share, totaling $19.8 million. This was part of the IPO completed on May 4, 2026.

• Lock-Up and Investor Rights Agreements

  The reporting persons are subject to a 180-day lock-up agreement from April 30, 2026, restricting share sales, and hold customary demand and piggyback registration rights exercisable after this period.

auto_awesomeAnalysis

Access Industries, led by Len Blavatnik, has disclosed a significant 10.4% beneficial ownership stake in Hemab Therapeutics Holdings, Inc. following its recent initial public offering. This includes a direct purchase of 1.1 million shares in the IPO at $18.00 per share, demonstrating substantial institutional confidence in the company's prospects shortly after its market debut. This investment, made at a price below the current market value, signals strong conviction from a major investor.